Stentys has received CE marking for its self-expanding drug-eluting stent. Reportedly, in December 2009 it has started enrolling patients in the randomized APPOSITION II clinical trial to compare the Stentys self-expanding stent against conventional stents in treating AMI patients, looking specifically at stent apposition and adaptation to vessel growth.
The self-expanding Stentys stent is designed to ensure optimal apposition of a stent in the critical initial hours and days after an AMI (acute myocardial infarction) procedure, by being continuously applied to the vessel’s internal wall even during thrombus resolution and vessel spasm relief, thereby avoiding malapposition, a major predictor of stent thrombosis.
Gonzague Issenmann, CEO and co-founder of Stentys, said: “The clinical results of the Stentys DES in complex lesions have been spectacular, and we are thrilled that patients throughout Europe will have access to the benefits of our self-expanding stent in due course.”
Stentys was co-founded by Gonzague Issenmann and Jacques Seguin, founder of CoreValve, which was acquired last year by Medtronic for $700 million plus earn-outs.